Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-03-08 Sale |
2024-03-12 1:45 pm |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
25,000 | $5.1874 | $129,685 | 1,034,476 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-03-09 Tax Withholding |
2024-03-12 1:47 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | TOTH A ERNEST JR SVP, Chief Financial Officer |
11,705 | $4.88 | 248,295 (Direct) |
View |
| 2024-03-09 Tax Withholding |
2024-03-12 1:46 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Wargacki Stephen SVP, Research & Development |
12,956 | $4.88 | 257,963 (Direct) |
View |
| 2024-03-09 Tax Withholding |
2024-03-12 1:46 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Jung Cassie SVP, Operations |
9,432 | $4.88 | 239,798 (Direct) |
View |
| 2024-03-09 Tax Withholding |
2024-03-12 1:45 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
5,895 | $4.88 | 1,034,476 (Direct) |
View |
| 2024-03-07 Option Award |
2024-03-11 10:36 am |
N/A 2034-03-07 |
Aquestive Therapeutics Inc. | AQST | BRAENDER LORI J SVP, General Counsel |
202,500 | $0 | 391,261 (Direct) |
View |
| 2024-03-07 Option Award |
2024-03-11 10:36 am |
N/A 2034-03-07 |
Aquestive Therapeutics Inc. | AQST | TOTH A ERNEST JR SVP, Chief Financial Officer |
180,000 | $0 | 320,000 (Direct) |
View |
| 2024-03-07 Option Award |
2024-03-11 10:36 am |
N/A 2034-03-07 |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
123,750 | $0 | 1,106,621 (Direct) |
View |
| 2024-03-07 Option Award |
2024-03-11 10:35 am |
N/A 2034-03-07 |
Aquestive Therapeutics Inc. | AQST | Kraus Carl N Chief Medical Officer |
168,750 | $0 | 318,750 (Direct) |
View |
| 2024-03-07 Option Award |
2024-03-11 10:35 am |
N/A 2034-03-07 |
Aquestive Therapeutics Inc. | AQST | Barber Daniel President and CEO |
606,500 | $0 | 1,247,202 (Direct) |
View |
| 2023-03-10 Tax Withholding |
2024-03-11 10:35 am |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Jung Cassie SVP, Operations |
1,365 | $0 | 299,855 (Direct) |
View |
| 2024-03-07 Option Award |
2024-03-11 10:35 am |
N/A 2024-03-07 |
Aquestive Therapeutics Inc. | AQST | Jung Cassie SVP, Operations |
151,875 | $0 | 299,855 (Direct) |
View |
| 2024-03-07 Option Award |
2024-03-11 10:35 am |
N/A 2034-03-07 |
Aquestive Therapeutics Inc. | AQST | Boyd Peter E. See Remark |
129,375 | $0 | 289,123 (Direct) |
View |
| 2024-03-07 Option Award |
2024-03-11 10:34 am |
N/A 2034-03-07 |
Aquestive Therapeutics Inc. | AQST | Wargacki Stephen SVP, Research & Development |
168,750 | $0 | 327,169 (Direct) |
View |
| 2023-03-10 Tax Withholding |
2024-03-11 10:34 am |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Wargacki Stephen SVP, Research & Development |
1,981 | $0.7937 | 327,169 (Direct) |
View |
| 2023-08-09 Option Award |
2023-08-09 4:30 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | BRAENDER LORI J SVP, General Counsel |
75,000 | $0 | 75,000 (Direct) |
View |
| 2023-08-09 Option Award |
2023-08-09 4:30 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Barber Daniel President and CEO |
223,500 | $0 | 223,500 (Direct) |
View |
| 2023-08-09 Option Award |
2023-08-09 4:30 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Boyd Peter E. See Remark |
50,000 | $0 | 50,000 (Direct) |
View |
| 2023-08-09 Option Award |
2023-08-09 4:30 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer |
75,000 | $0 | 75,000 (Direct) |
View |
| 2023-08-09 Option Award |
2023-08-09 4:30 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Kraus Carl N Chief Medical Officer |
150,000 | $0 | 150,000 (Direct) |
View |
| 2023-08-09 Option Award |
2023-08-09 4:30 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Wargacki Stephen SVP, Research & Development |
67,500 | $0 | 67,500 (Direct) |
View |
| 2023-08-09 Option Award |
2023-08-09 4:30 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | TOTH A ERNEST JR SVP, Chief Financial Officer |
70,000 | $0 | 70,000 (Direct) |
View |
| 2023-08-09 Option Award |
2023-08-09 4:30 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
50,000 | $0 | 50,000 (Direct) |
View |
| 2023-08-09 Option Award |
2023-08-09 4:30 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Jung Cassie SVP, Operations |
55,000 | $0 | 55,000 (Direct) |
View |
Ownership |
2023-06-30 4:06 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Kraus Carl N CHIEF MEDICAL OFFICER |
0 | $0 | 0 (Direct) |
View |
| 2023-06-21 Option Award |
2023-06-23 1:41 pm |
2024-06-21 2033-06-21 |
Aquestive Therapeutics Inc. | AQST | BROWN GREGORY B Director |
25,000 | $0 | 100,085 (Direct) |
View |
| 2023-06-21 Option Award |
2023-06-23 12:28 pm |
2024-06-21 2033-06-21 |
Aquestive Therapeutics Inc. | AQST | Krop Julie Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2023-06-21 Option Award |
2023-06-23 12:27 pm |
2024-06-21 2033-06-21 |
Aquestive Therapeutics Inc. | AQST | MORRIS TIMOTHY E Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2023-06-21 Option Award |
2023-06-23 12:26 pm |
2024-06-21 2033-06-21 |
Aquestive Therapeutics Inc. | AQST | Taglietti Marco Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2023-06-21 Option Award |
2023-06-23 12:26 pm |
2024-06-21 2033-06-21 |
Aquestive Therapeutics Inc. | AQST | COSTA SANTO J Director |
25,000 | $0 | 42,327 (Direct) |
View |
| 2023-06-21 Option Award |
2023-06-23 12:24 pm |
2024-06-21 2033-06-21 |
Aquestive Therapeutics Inc. | AQST | Cochran John Director |
25,000 | $0 | 124,486 (Direct) |
View |
| 2023-05-05 Option Award |
2023-05-05 4:00 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Wargacki Stephen SVP, Research & Development |
67,500 | $0 | 67,500 (Direct) |
View |
| 2023-05-05 Option Award |
2023-05-05 4:00 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | TOTH A ERNEST JR SVP, Chief Financial Officer |
70,000 | $0 | 70,000 (Direct) |
View |
| 2023-05-05 Option Award |
2023-05-05 4:00 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
50,000 | $0 | 50,000 (Direct) |
View |
| 2023-05-05 Option Award |
2023-05-05 4:00 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | BRAENDER LORI J SVP, General Counsel |
75,000 | $0 | 75,000 (Direct) |
View |
| 2023-05-05 Option Award |
2023-05-05 4:00 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Barber Daniel President and CEO |
223,500 | $0 | 223,500 (Direct) |
View |
| 2023-05-05 Option Award |
2023-05-05 4:00 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer |
75,000 | $0 | 75,000 (Direct) |
View |
| 2023-05-05 Option Award |
2023-05-05 4:00 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Jung Cassie SVP, Operations |
55,000 | $0 | 55,000 (Direct) |
View |
| 2023-05-05 Option Award |
2023-05-05 4:00 pm |
N/A 2026-05-05 |
Aquestive Therapeutics Inc. | AQST | Boyd Peter E. See Remark |
50,000 | $0 | 50,000 (Direct) |
View |
| 2023-03-09 Option Award |
2023-03-09 3:07 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Boyd Peter E. See Remark |
100,000 | $0 | 159,532 (Direct) |
View |
| 2023-03-09 Option Award |
2023-03-09 3:07 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer |
150,000 | $0 | 151,445 (Direct) |
View |
| 2023-03-09 Option Award |
2023-03-09 3:07 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Jung Cassie SVP, Operations |
110,000 | $0 | 148,791 (Direct) |
View |
| 2023-03-09 Option Award |
2023-03-09 3:07 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
100,000 | $0 | 982,871 (Direct) |
View |